Anti-cancer activity of novel dibenzo[b,f]azepine tethered isoxazoline derivatives by Maralinganadoddi Panchegowda Sadashiva, . et al.
Sadashiva et al. BMC Chemical Biology 2012, 12:5
http://www.biomedcentral.com/1472-6769/12/5RESEARCH ARTICLE Open AccessAnti-cancer activity of novel dibenzo[b,f]azepine
tethered isoxazoline derivatives
Maralinganadoddi Panchegowda Sadashiva1†, Basappa2,3†, Shivananju NanjundaSwamy4, Feng Li4,
Kanjoormana Aryan Manu4, Murugan Sengottuvelan2, Doddakunche Shivaramu Prasanna1,
Nirvanappa Chikkagundagal Anilkumar3, Gautam Sethi4, Kazuyuki Sugahara2 and
Kanchugarakoppal Subbegowda Rangappa1*Background: Dibenzoazepine (DB) derivatives are important and valuable compounds in medicinal chemistry. The
synthesis and chemotherapeutic properties of naturally occurring DBs and different heterocyclic moiety tethered
DBs are reported. Herein, we report the DB-fused hybrid structure that containing isoxazolines (DBIs) and their
anti-cancer activity, which could throw light on the structural and functional features of new molecules.
Results and Conclusion: The synthesis and characterization of novel ring DB tethered isoxazoline derivatives (DBIs)
were carried out. After the detailed structural characterization using 2D-NMR experiments, the compounds were
identified as 5-substituted isoxazolines. The effect of newly synthesized DBIs against the invasion of murine
osteosarcoma (LM8G7) cells was studied. Among the tested molecules, compound 4g (5-[−3-(4-chlorophenyl)-4,5-
dihydroisoxazol-5-yl-methyl]-5H-dibenzo[b,f]azepine), was found to inhibit the invasion of LM8G7 cells strongly,
when compared to other structurally related compounds. Cumulatively, the compound 4g inhibited the invasion
MDA-MB-231 cells completely at 10 μM. In addition to anti-invasion property the compound 4g also inhibited the
migration of LM8G7 and human ovarian cancer cells (OVSAHO) dose-dependently. Compound 4g inhibited the
proliferation of LM8G7, OVSAHO, human breast cancer cells (MCF-7) and human melphalan-resistant multiple
myeloma (RPMI8226-LR5) cells that are comparable to cisplatin and suramin.
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Tricyclic compounds like phenothiazine, acridones, phe-
noxazines, benzodiazepines and dibenzoazepines are
very important class of anticancer agents. Earlier studies
have demonstrated that, altering the polarity (incorpor-
ation of hydrophilic or hydrophobic groups) at N-pos-
ition play a vital role to augument the biological activity
(Figure 1) [1,2]. Dibenzoazepine (DB) is a diversified
core moiety which exhibit antiviral, antiepileptic, antic-
onvulasant, antimicrobial, antimalarial and anticancer
activities [3-5]. 5H-dibenzo[b,f]azepine-5-carboxamide
(carbamazepine) is one of the synthesized effective anti-
convulsant drugs, which is the most frequently pre-
scribed first-line drug for the treatment of epilepsy [6].* Correspondence: rangappaks@gmail.com
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reproduction in any medium, provided the orDB-based small molecules are reported to show antioxi-
dant activity and also sirtuin-2 inhibitory activity [7,8].
Azepine moiety containing tricyclic and naturally occur-
ring pyrrolo[2,1-c][1,4]benzodiazepines originated from
Streptomyces species, are used as antitumor and antibio-
tics [9,10]. These compounds exhibit cytotoxic activity
by covalent bonding between the C11-position of tricyc-
lic azepine moiety and the N2 of the guanine residues of
the minor groove of DNA [11,12]. Synthesis and antic-
ancer activity of tricyclc azepine moiety tethered with pi-
perazine and 1,2,3-triazole moiety are well reported [13].
Several chemical modifications of dibenzoazepine (DB)
conjugated to known active moieties of heterocycles to
improve the anti-cancer activity has been attempted.
However they have not considered for clinical studies
due to the problems relating to side effects.
Nucleosides are the building blocks of DNA and be-
come a key molecule in the field of medicinal chemistry
for the discovery of new natural nucleoside derivatives.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
X= S, C 2H 2, C 2H 4
R 1, R 2= CH 3, C 2H 5, Pyrrolidinyl,benzyl.....
Figure 1 General structure of dibenzo-azepines.
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both the heterocyclic base as well as on the sugar moi-
ety. Mainly, the replacement of the ribose ring with an
isoxazolidine nucleus has emerged as an interesting class
of dideoxynucleoside analogues [14-16]. These analogues
undergo phosphorylation by cellular kinases and meta-
bolized by enzymatic systems instead of natural nucleo-
sides, inserted in the DNA growing chain, and finally
acting as chain terminators [17,18].
In continuation of our effort to synthesise novel DBs
and isoxazoli(di)ne derivatives [19-21] herein we report
the synthesis of DB-fused hybrid structure that contain-
ing isoxazolines (DBIs) and their anti-cancer activity,
which could throw light on the structural and functional
features of new molecules.Results and Discussion
The dipolarophile 2 was prepared by the reaction of
commercially available iminostilbene 1 with allylbromide
[22]. The N-allyl pendant arrangement of the intermedi-
ate 2 showed a major role in the formation of product.
It means that, product will be obtained on the basis of
either allyl pendant bent towards the tricyclic ring or
disposed outside the ring. The X-ray crystallographic
studies revealed that the pendant is disposed outside
from the tricyclic aromatic ring [22].
The oxime 3 was prepared by the reaction of corre-
sponding aldehyde with hydroxylamine in the presence
of sodiumbicarbonate in EtOH/H2O at 60°C [19]. With
two scaffolds in hand, the dibenzoazepine derivatives
were synthesized in a single step operation via successive
1,3-dipolar cycloaddition reaction. A solution of oxime 3NN
H
a
1 2
Scheme 1 Reagents and reaction conditions: a) 2 equiv allyl bromide
oxime, 5 equiv 4% NaOCI, 1 equiv Et3N in MDC.(2 eq) in dichloromethane was added to a mixture of
N-allyl tricyclic amine 2 (1 eq), sodium hypochlorite (4%
aqueous solution, 5 eq) and Et3N (0.05 eq) as shown in
Scheme 1.
Progress of the reaction was monitored using TLC.
After completion of the reaction, the compounds 4(a-h)
were purified using column chromatography. The struc-
tures of the final products as well as intermediate were
confirmed by NMR, mass and elemental analysis.
The proton assignment and regioisomer of the title
compound was studied using 1H, 13C NMR and 2D
NMR experiments (HMQC, HMBC, and COSY)
(Tables 1 and 2). The chemical shift of geminal protons
(H4a, H4e) and methine proton (H5) of isoxazoline ring
were observed at 3.18, 3.36 and 4.91 ppm (13C; C-4; 3.18
and C-5; 78.17 ppm) respectively. The calculated chem-
ical shifts for geminal protons 4-substituted isoxazoline
was assigned at ~5.0 ppm due to the neighboring
O-atom effect [23] (Figure 2). Further, HMBC experi-
ment also gave the significant information for the regios-
electivity. The geminal protons H4a, H4e showing the
cross peak with C-3 (−C = N-) of isoxazoline ring. Simi-
larly, C-5 signal gave cross peak with geminal protons
H4a, H4e but not with C-3 (−C = N-) (Table 1). The
above data strongly suggested that, the obtained product
is 5-substituted isoxazoline.Biology
DBIs inhibited the invasion of murine osteosarcoma and
human breast cancer cells
Invasion and metastasis are the life-threatening aspects
of cancer cells [24]. Most of the cancers unmask theirR N
OH
N
N
O
R
b
3
4
, 2.5 equiv K2CO3 in acetonitrile at reflux condition. b) 5 equiv
Table 1 1H and 13C NMR (HMQC and HMBC) data of the compound, 5-[-3-(4-Chlorophenyl)-4,5-dihydroisoxazol-5-
ylmethyl]-5H dibenzo[b,f]azepine
HMBC HMQC
Carbon C4 C6 C5 Carbon C4 C6 C5
Proton δ ppm 38.35 53.7 78.7 Proton δ ppm 38.35 53.7 78.7
H4a 3.153 Bonded β α H4ax 3.153 Bonded
H4b 3.20 Bonded β α H4eq 3.20 Bonded
H6a 3.483 β Bonded α H6a 3.483 Bonded
H6b 4.295 β Bonded α H6b 4.295 Bonded
H5 4.886 α β Bonded H5 4.886 Bonded
α= 2J(C,H).
β= 3J(C,H).
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lignancy from pre-existing carcinoma in situ, or from
disorders of epithelial proliferation. Hence, we initially
studied the effects of DBIs on the invasion of highly
metastatic murine osteosarcoma (LM8G7) cells using
MatrigelTM-coated porous membranes. The LM8G7
cells were highly invasive in the assay. The efficacy of
the compounds against the invasion of LM8G7 was
summarized. Among the tested DBIs, 4g at 1 and 5 μM
concentration inhibited the invasion of LM8G7 cells by
67 and 85%, respectively. The results indicated that the
compound 4g exhibited dose-dependent anti-invasive
property against the LM8G7 cells, when compared to
the other structurally similar derivatives (Figure 3). Sura-
min inhibited the invasion of LM8G7 cells by 73 and
94% at 1 and 5 μM, respectively (data not shown).Table 2 2D-NMR data (COSY) of the compound, 5-[-3-(4-
chlorophenyl)-4, 5-dihydroisoxazol-5-yl methyl]-5H
dibenzo [b,f]azepine
H-H-COSY 1H NMR 13C NMR
Position Chemical Shifts
in ppm
Position δ ppm 1H δ ppm 13C
H4a 3.153/3.208
3.153/4.886 H4ax (C-4) 3.18 38.15
H4b 3.208/3.153
3.208/4.886 H4eq (C-4) 3.36 38.15
H6a 3.483/4.295
3.483/4.886 H6a (C-6) 3.59 53.7
H6b 4.295/3.483
4.295/4.886 H6b (C-6) 4.31 53.7
H5 4.886/3.153
4.886/3.208
4.886/3.483
4.886/4.296 H5 (C-5) 4.91 78.7
C-3 155.56
Ar-H 6.5-7.7 120-136Furthermore, we selected the compound 4g and evalu-
ated its effect on the invasion of human breast cancer
cells (MDA-MB-231) in vitro. The results of the study
revealed that the compound 4g completely suppressed
the invasion of MDA-MB-231 cells in a dose-dependent
manner (Figure 4).
Compound 4g inhibited the migration of tumor cells
Metastatic tumor cells can migrate from one place to
another in the body. So, the effect of compound 4g
against the migration of LM8G7 cells was studied. Boy-
don Chamber assay was performed to examine its effect
on migration. Compound 4g inhibited the migration of
LM8G7 cells dose dependently (Figure 5) at 0.5 and
1 μM by 47 and 78% respectively. Furthermore, the
compound 4g also inhibited the migration of human
ovarian (OVSAHO) cells by 40.2 and 84.9% at 0.5 and
1.0 μM, respectively (data not shown).
Compound 4g inhibited the proliferation of tumor cells
We monitored the effects of compound 4g on the prolif-
eration of LM8G7 or OVSAHO cells using real-time cell
electronic sensing systemTM (RT-CES). The effects of
compound 4g on the proliferation of LM8G7 or
OVSAHO cells were monitored dynamically for everyFigure 2 Representation of 5-substituted (a) and 4-substituted
(b) isoxazoline rings.
Figures 3 DBIs inhibited the invasion of LM8G7 cells. LM8G7 cells were seeded in Boyden-chambers in triplicate and incubated for 24 h with
DMEM or a medium containing 1 or 5 μM of DBIs derivatives. The cell invasion and its inhibition by DBIs were measured. The % inhibition of the
invasion of LM8G7 cells by DBIs was given. The data represent the mean value ± S.D. for three independent experiments. *P < 0.05 versus control,
**p 0.01 versus control, ***p 0.001 versus control, Mann–Whitney U test.
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LM8G7 and OVSAHO cells dose-dependently with an
IC50 value of 15 μM and 24 μM, respectively proved its
anti-proliferative effect on tumor cells (Figure 6 and 7).Figure 4 Compound 4g completely inhibited the invasion of MDA-MB
and were incubated for 24 h with DMEM (untreated) or a medium contain
the photographs shows the cell on the lower surface of the filter (invaded)
of MDA-MB-231 by compound 4g was presented. The data represent the m
control, Student's t-test.We next investigated the anti-proliferative effect of com-
pound 4g on human melphalan-resistant multiple mye-
loma (RPMI8226/LR5) cells using MTT assay. It is
observed that the compound 4g exerts anti-proliferative-231 cells. Cells were seeded in MatrigelTM-coated Boyden chambers
ing 1 μM of compound 4g (1 μM) or 10 μM compound 4g (10 μM);
stained with the Diff-Quick solution. The % inhibition of the invasion
ean value ± S.D. for three independent experiments. * P < 0.05 versus
Figure 5 Compound 4g inhibited the migration of LM8G7 cells. Cells were seeded in control-Boyden chambers and were incubated for 24 h
with DMEM or a medium containing 0.5 or 1 μM of compound 4g; the photographs shows the cell on the lower surface of the filter (migrated)
stained with Diff-Quick solution. The % inhibition of the migration of LM8G7 by compound 4g was presented. The data represent the mean
value ± S.D. for two independent experiments. * P < 0.05 versus control, ** p 0.01 versus control, Mann–Whitney U test.
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(Figure 8). Furthermore, we investigated the anti-
proliferative effect of the compound 4g on human breast
cancer (MCF-7) cells. As shown in Figure 9a, it was
observed that the compound 4g exerts anti-proliferative
effects on MCF-7 cells at various tested concentrations
when compared to the control group. Interestingly, we
observed that compound 4g had little or no anti-Figure 6 Real-time monitoring of the effects of compound 4g on the
e-plateTM at a density of 5 x 103 cells per well in triplicate, and continuousl
compound 4g (12 to 75 μM) was added. The cell index is plotted against t
wells from three independent experiments. *p 0.05 versus control, Mann–Wproliferative effect on MCF-10A cells, indicating that it
is not substantially cytotoxic to normal cells (Figure 9b).
On the other hand, compound 4g moderately inhibited
the proliferation of mouse endothelial cells (UV♀2) with
an IC50 value of 62 μM (Table 3). These results show
that compound 4g suppressed the proliferation of endo-
thelial cells, but the concentration of compound 4g
required to suppress cell proliferation is high. Theproliferation of LM8G7 cells. LM8G7cells were seeded in ACEA’s 96X
y monitored using the RT-CES system up to 24 h, at which point
he time. Data represent the mean values ± S.D. for three identical
hitney U test.
Figure 7 Real-time monitoring of the effects of compound 4g on the proliferation of OVSAHO cells. OVSAHO cells were seeded in ACEA’s
96X e-plateTM at a density of 5 x 103 cells per well and continuously monitored using the RT-CES system up to 24 h, at which point compound
4g was added. The cell index is plotted against the time. Data represent the mean values ± S.D. for three identical wells from three independent
experiments. *p 0.05 versus control, **p 0.01 versus control, Mann–Whitney U test.
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of reference molecules such as cisplatin and suramin.Compound 4g can induce apoptosis in tumor cells
We evaluated the effect of compound 4g to induce
apoptosis in tumor cells to detect early stage of apop-
tosis. The results indicate that the compound 4g can in-
duce significant apoptosis in a time dependent manner
in MCF-7 cells (Figure 10).Figure 8 Anti-proliferative effects of compound 4g on
RPMI8226-LR5 cells. Cells (20 x 103/100 μl) were plated in triplicate,
treated with 0, 5, 10, 15, and 30 μM compound 4g, and then
subjected to MTT assay on days 1, 2, and 3, to analyze proliferation
of cells. Data represent the mean values ± S.D..Absorption–distribution–metabolism–excretion–toxicity
(ADMET) properties of DBIs
In silico ADMET properties for all the newly synthesized
compounds were obtained using Discovery Studio
programme (Accelrys Inc., USA). All the DBIs are in ac-
cordance with the parameters of the Lipinski’s Rule of
Five [25]. The absorption (PSA2D) parameter range was
23 to 66 and also the distribution (AlogP) parameters
range lies between 4.6 to 5.9 (Table 4). The ADMET-
human intestinal absorption model predicts that these
compounds could well absorb in the body. Probably,
these compounds are highly penetrable to the blood
brain barriers (BBB) after oral administration. Also, the
recursive partitioning/classification trees method pre-
dicts that the compound can inhibit the CYP2D6 en-
zyme weakly. These pharmacokinetic parameters well
within the acceptable range defined for human use,
thereby indicating their potential as drug-like or drug
seed molecules.
Conclusions
In conclusion, we herein report the incorporation of
isoxazoline ring tethered to dibenzo[b,f]azepine for the
first time. After the detailed structural characterization
using 2D-NMR experiments, the products were con-
firmed as 5-substituted isoxazolines. Among the tested
compounds, compound 4g was found to inhibit the in-
vasion of LM8G7 cells, when compared to other struc-
turally related DBIs. Also, the compound 4g inhibited
the invasion MDA-MB-231 cells completely at 10 μM.
Evident to invasion, the compound 4g also inhibited
the migration of LM8G7 and OVSAHO cells dose de-
pendently. As a result, inhibitory activity of compound
Figure 9 Anti-proliferative effects of compound 4g on MCF-7 or MCF-10A cells. MCF-7 or MCF-10A cells were plated in triplicate, treated
with 0, 5, 10, 15, and 30 μM of compound 4g, and then subjected to MTT assay on days 1, 2, and 3, to analyze proliferation of cells. *p 0.05 versus
control (15 μM, 72 h), **p 0.01 versus control (30 μM, 72 h), Mann–Whitney U test.
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RPMI8226/LR5 cells and was comparable to that of cis-
platin and suramin.
Methods
Chemical synthesis and reagents
Melting points were determined in capillaries on a Tot-
toli apparatus and are uncorrected. The NMR experi-
ments 1H, 13C, HMBC, HMQC were carried out at 500
(125) MHz and the reported chemical shifts (δ) are
given in ppm and the coupling constants (J) in Hertz
(Hz). Multiplicities of NMR signals are designed as s
(singlet), d (doublet), m (multiplet, for unresolved lines).
Mass spectra were recorded on a Trio 1000 Thermo
Quest spectrometer in the electron impact mode or a
Platform Micromass spectrometer in the electro spray
mode. TLC was performed on silica gel Alugram SilG/
UV254 (Macherey-Nagel). The murine osteosarcoma
cell line LM8G7, a highly metastatic murine osteosar-
coma cell line with the potential to form tumor nodules
in the liver, was cloned from LM8G5 cells as described
[26,27] and cultured in DMEM supplemented with 10%
FBS, streptomycin (100 μg/ml), penicillin (100 units/ml),Table 3 Inhibition of the proliferation of tumor and
endothelial cells by compound 4g
Compound Anti-proliferative activity (IC50 in μM)
LM8G7 OVSAHO UV♀2
4g 15± 0.6* 24± 3.6** 62± 1.9
Cisplatin 30 ± 24 15 ± 0.6 12 ± 0.4
Suramin 12 ± 2.8 14 ± 24 34 ± 1.4
*p 0.05 versus control, **p 0.01 versus control, Mann-Whitney U test.100X non-essential amino acids, β-mercaptoethanol
(50 μM), 100X sodiumpyruvate, and L-glutamine (2 mM)
at 37°C in a humidified 5% CO2 atmosphere. Human
ovarian cancer cells (OVSAHO) were procured from
ATCC and cultured in RPMI media supplemented with
10% FBS, L-glutamine (2 mM), and NaHCO3 (10%). The
cells were grown to 80 % confluency before passage, and
experiments were restricted to passages 5–20. The
human multiple myeloma (MM) cell line RPMI-8226-
LR-5 cells were cultured in RPMI 1640 mediumFigure 10 Compound 4g induces apoptosis in MCF-7 cells. Cells
were treated with 30 μM compound 4g for indicated times,
incubated with anti-annexin V antibody conjugated with FITC, and
analyzed with a flow cytometer for apoptotic effects. **p 0.05 versus
control, Student's t-test.
Table 4 ADMET-properties of the sugar mimetic isoxazoline molecules by use of Discovery Studio 2.5 version
Compounds BBB Solubility Hepatotoxicity CYP2D6 PPB level ADMET_AlogP98 ADMET_PSA_2D
4a 0.42 -6.73 0.96 0.90 2 5.28 66.42
4b 0.42 -6.70 0.94 0.84 2 5.28 66.42
4c 0.69 -6.49 0.80 0.83 2 5.33 50.39
4d 0.99 -6.64 0.93 0.92 2 5.37 32.53
4e 0.73 -6.13 0.92 0.92 2 4.66 34.86
4f 1.13 -6.76 0.95 0.96 2 5.38 23.60
4g 1.34 -7.36 0.91 0.85 2 5.98 23.60
4h 1.26 -7.20 0.96 0.75 2 5.79 23.60
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RPMI-8226-LR-5 and MCF-7 cells were cultured in
RPMI 1640 medium with 10% FBS supplemented with
100 U/mL penicillin and 100 μg/mL streptomycin. MCF-
10A cells were cultured in MEGMW mammary epithelial
cell complete medium obtained from Lonza, USA [28].
Synthesis of allyl-5 H dibenzo[b,f]azepine 2
The compound 2 was synthesized using the reported
method [22].
The product is yellow solid. mp: 40–42°C. 1H NMR
(δ ppm, CDCl3, 500 MHz): δ 4.4 (d, 2 H J= 14 Hz), 5.12
(dd, 2 H), 5.28 (dd, 2 H), 5.8 (m, 1 H), 6.76 (s, 2 H), 7.08
(d, 2 H J= 5 Hz), 6.98–7.12 (q, 4 H), 7.2–7.3 (t, 2 H).IR
KBr (cm-1): 1315, 1642, 3040, 3072. Anal. Calcd for
C17H15N: C, 87.6; H, 6.49; N, 6.0. Found: C, 87.63; H,
6.43; N, 6.0.
General procedure for the DBIs
The weighed amount of aldoxime 3 (2 eq) was dissolved
in 10 mL of methylene dichloride taken in a round bot-
tom flask. The solution was made basic using triethyla-
mine (0.05 eq). 2 equivalents of sodiumhypochlorite,
followed by tricyclicamine (1 equiv) 2, were added
slowly at 0°C to the stirring solution. After complete
addition of the reactants stirring was continued until the
reaction is completed. The crude residue was purified by
silica gel column chromatography eluting with a mixture
of n-hexane and ethyl acetate with successive increasing
the quantity of ethyl acetate, affording the corresponding
product 4(a-h).
5-[−3-(2-nitrophenyl)-4,5-dihydroisoxazol-5-yl-me-
thyl]-5 H-dibenzo[b,f] azepine 4a The product is a
thick liquid. Yield: 0.229 g (67.3%).1 H NMR (δ ppm,
CDCl3, 500 MHz): δ 3.28 (dd, 1 H, H4a, J-14.4, 7.5 Hz);
3.37 (dd, 1 H, H4e, J-14.4, 5.2 Hz); 3.51 (dd, 1 H, H6a,
J-12.1, 7.8 Hz); 4.33 (dd, 1 H, H6e, J-12.1, 4.1 Hz); 4.88
(m, 1 H, H5); 6.76 (d, 2 H, CH, J-2.1 Hz); 7.1-8.20 ( m,
12 H, Ar-H). 13C NMR (δ ppm, CDCl3, 125 MHz):
δ 38.2 (C-4), 55.6 (C-6), 77.5 (C-5), 124 (CH), 127–144.0(Ar-C), 158.2 (C-C = N). MS (ESI + ion): m/z = 398.1 [M
+ H] +. Anal. calcd for C24 H19 N3O3: C, 72.53; H, 4.82;
N, 10.57. Found : C, 72.45; H, 4.86; N, 10.48.
5-[−3-(3-nitrophenyl)-4, 5-dihydroisoxazol-5-yl-methyl]-5 H-
dibenzo[b,f]azepine 4b
The product is a thick liquid. Yield: 0.224g (65.7 %). 1 H
NMR (δ ppm, CDCl3, 500 MHz): δ 3.24 (dd, 1 H, H4a, J-
14.1, 7.2 Hz); 3.37 (dd, 1 H, H4e, J-14.1, 5.0 Hz); 3.45
(dd, 1 H, H6a, J-12.8, 6.8 Hz); 4.33 (dd, 1 H, H6e, J-12.8,
4.6 Hz); 4.77 (m, 1 H, H5); 6.70 (d, 2 H, CH, J-2.1 Hz);
7.4-8.26 (m, 12 H, Ar-H). 13C NMR (δ ppm, CDCl3,
125 MHz): δ 38.6 (C-4), 54.3 (C-6), 76.4 (C-5), 125.2
(CH), 130–146.2 (Ar-C), 154.8 (C-C = N). MS (ESI +
ion): m/z = 398.6 [M + H] +. Anal. calcd for C24 H19
N3O3: C, 72.53; H, 4.82; N, 10.57. Found : C, 72.48; H,
4.78; N, 10.41.
5-[−3-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazol-
5-yl-methyl]5 H-dibezo[b,f] azepine 4c The product is
a thick liquid. Yield: 0.260 g (68.6%). 1 H NMR (δ ppm,
CDCl3, 500 MHz): δ 3.21 (dd, 1 H, H4a, J-15.8, 9.6 Hz);
3.30 (dd, 1 H, H4e, J-15.8, 6.1 Hz); 3.48 (dd, 1 H, H6a, J-
12.5, 8.1 Hz); 3.76 (s, 6 H, OCH3); 3.79(s, 3 H, OCH3);
4.28 (dd, 1 H, H6e, J-13.1, 4.4 Hz); 4.84 (m, 1 H, H5);
6.78 (d, 2 H, CH, J-2.2 Hz); 6.82-7.42 (m, 10 H, Ar-H).
13C NMR (δ ppm, CDCl3, 125 MHz): δ 37.5 (C-4), 54.7
(C-6), 56.4 (OCH3), 76.9 (C-5), 126 (CH), 128–134.0
(Ar-C), 156.6 (C-C = N). MS (ESI + ion): m/z = 443.5 [M
+ H] +. Anal. calcd for C27 H26 N2O4: C, 73.2; H, 5.92;
N, 6.33. Found : C, 73.15; H, 5.86; N, 6.28.
5-[−3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl-
methyl]-5 H-dibenzo[b,f] azepine 4d The product is a
thick liquid. Yield: 0.214g (65.3 %). 1 H NMR (δ ppm,
CDCl3, 500 MHz): δ 3.24 (dd, 1 H, H4a, J-16.8, 9.8 Hz);
3.36 (dd, 1 H, H4e, J-16.8, 6.8 Hz); 3.50 (dd, 1 H, H6a,
J-14.8, 8.8 Hz); 3.72 (s, 3 H, OCH3); 4.30 (dd, 1 H, H6e,
J-14.8, 4.5 Hz); 4.88 (m, 1 H, H5); 6.64 (d, 2 H, CH,
J-2.8 Hz); 6.82-7.32 ( m, 12 H, Ar-H). 13C NMR (δ ppm,
CDCl3, 125 MHz): δ 36.2 (C-4), 53.8 (C-6), 56.8 (OCH3),
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N). MS (ESI + ion): m/z = 383.75 [M + H] +. Anal. calcd
for C25 H22 N2O2: C, 78.51; H, 5.80; N, 7.32. Found :
C, 78.58; H, 5.89; N, 5.68.
Synthesis of 5-[−3-(pyridyl)-4,5-dihydroisoxazol-5-yl-methyl]-
5 H-dibenzo [b,f] azepine 4e
The product is thick liquid. Yield: 0.22 g (72.6 %). 1H
NMR (δ ppm, CDCl3, 500 MHz): δ 2.88 (dd, 1 H, H4a, J-
16.7, 10.7 Hz); 3.28 (dd, 1 H, H4e, J-16.5, 6.0 Hz); 3.39
(dd, 1 H, H6a, J-13.0, 9.0 Hz); 4.27 (dd, 1 H, H6e, J-12.5,
4.5 Hz); 4.72 (m, 1 H, H5); 6.70 (d, 2 H, CH, J-2.5 Hz);
6.52-8.22 (m, 12 H, Ar-H). 13C NMR: δ 36.4 (C-4), 51.8
(C-6), 75.51 (C-5), 124.22 (CH), 124–152.9 (Ar-C),
158.21 (C-C = N). MS (ESI + ion): m/z =354.0 [M + H]
+. Anal. calcd for C23 H19 N3O: C, 78.16; H, 5.42; N,
11.89. Found : C, 78.21; H, 5.34; N, 11.78.
5-[−3-(phenyl)-4,5-dihydroisoxazol-5-yl-methyl]-5 H-
dibenzo[b,f]azepine 4(f The product is yellow thick li-
quid. Yield: 0.23 g (72.3 %). 1 H NMR (δ ppm, CDCl3,
500 MHz): δ 3.11 (dd, 1 H, H4a, J-15.0, 10.2 Hz); 3.28
(dd, 1 H, H4e, J-15.0, 5.4 Hz); 3.48 (dd, 1 H, H6a, J-12.5,
8.5 Hz); 4.28 (dd, 1 H, H6e, J-12.3, 4.1 Hz); 4.84 (m, 1 H,
H5); 6.73 (d, 2 H, CH, J-2.5 Hz); 7.00-7.33 (m, 13 H, Ar-
H). 13C NMR (δ ppm, CDCl3, 125 MHz): δ 36.10 (C-4),
51.25 (C-6), 75.81 (C-5), 121 (CH), 122–131.0 (Ar-C),
153.00 (C-C = N). MS (ESI + ion): m/z =353.1 [M + H]
+. Anal. calcd for C24 H19 N2FO: C, 77.82; H, 5.17; N,
7.56. Found : C, 77.9; H, 5.21; N, 7.48.
5-[-3-(4-chlorophenyl)-4,5-dihydroisoxazol-5-yl-me-
thyl]-5 H-dibenzo[b,f] azepine 4g The product is
yellow solid. Yield: 0.25 g (75 %). mp-156–158°C. 1H
NMR (δ ppm, CDCl3, 500 MHz): δ 3.15 (dd, 1 H, H4a,
J-16.7, 10.7 Hz); 3.20 (dd, 1 H, H4e, J-16.5, 6.0 Hz); 3.45
(dd, 1 H, H6a, J-13.0, 9.0 Hz); 4.30 (dd, 1 H, H6e, J-12.5,
4.5 Hz); 4.29 (m, 1 H, H5); 6.73 (d, 2 H, CH, J-2.5 Hz);
7.00-7.52 (m, 12 H, Ar-H). 13C NMR (δ ppm, CDCl3,
125 MHz): δ 38.54 (C-4), 53.78 (C-6), 78.71 (C-5), 124
(CH), 127–135.9 (Ar-C), 155.56 (C-C = N). MS (ESI +
ion): m/z =387.0 [M + H] +. Anal. calcd for C24 H19
N2ClO: C, 74.51; H, 4.95; N, 7.24. Found : C, 75.08; H,
5.14; N, 7.08.
5-[-3-(2,6-difluorophenyl)-4,5-dihydroisoxazol-5-yl-methyl]-
5 H-dibenzo[b,f] azepine 4h
The product is thick liquid. Yield: 0.209 g (69.2 %). 1H
NMR (δ ppm, CDCl3, 500 MHz): δ 3.11 (dd, 1 H, H4a, J-
14.7, 9.8 Hz); 3.24 (dd, 1 H, H4e, J-14.7, 5.5 Hz); 3.48
(dd, 1 H, H6a, J-12.0, 7.0 Hz); 4.31 (dd, 1 H, H6e, J-12.0,
3.8 Hz); 4.71 (m, 1 H, H5); 6.68 (d, 2 H, CH, J-2.2 Hz);
6.8-7.62 (m, 11 H, Ar-H). 13C NMR (δ ppm, CDCl3,
125 MHz): δ 34.70 (C-4), 51.80 (C-6), 76.61 (C-5),123.75 (CH), 128.8-165.9 (Ar-C), 158.80 (C-C = N). MS
(ESI + ion): m/z =389.14 [M + H] +. Anal. calcd for C24
H18 N2F2O: C, 74.21; H, 4.67; N, 7.21. Found : C, 74.11;
H, 4.54; N, 7.10.
Invasion assay
The in vitro invasion assay was performed using bio-
coat Matrigel invasion assay system (BD Biosciences,
San Jose, CA, USA), according to the manufacturer’s
instructions. MDA-MB-231 cells (2 × 105 cells) or
LM8G7 cells (2.5 x 104) were suspended in serum-free
RPMI 1640 medium or DMEM, respectively and seeded
into the Matrigel transwell chambers consisting of poly-
carbonate membranes with 8-μm pores [29]. After incu-
bation with 1 or 10 μM concentrations of DBIs for 24 h,
the upper surfaces of the transwell chambers were wiped
with cotton swabs and the invading cells were fixed and
stained with crystal violet solution. The invading cell
numbers were counted in five randomly selected micro-
scope fields. The % inhibition of the invaded cells was
calculated.
In vitro migration assay
The efficacy of LM8G7 cell migration was assessed using
the BD BioCoatTM chamber (8 μm PET pores) without
Matrigel (BD Biosciences, 8 μm pore size, insert size:
6.4 μm) in vitro [29]. Briefly, single cell suspensions of
LM8G7 cells (2.5 x 104) were prepared by detaching and
resuspending the cells in DMEM containing 0.1 % BSA.
Before the cells were added, the chambers were rehy-
drated for 2 h in an incubator at 37°C. The lower cham-
bers were filled with DMEM containing 5 % FBS. To the
upper chamber, LM8G7 or OVSAHO cells and com-
pound 4g in serum-free DMEM was added. After incu-
bation for 24 h, cells that had passed through the BD
BioCoatTM chamber and remained attached to the op-
posite surface of the membrane are stained with Diff-
Quick solution and counted in five random microscopic
fields per filter. The % inhibition of the migration of
LM8G7 or OVSAHO cells by compound 4g was
calculated.
Real-time cell proliferation assay
The cell proliferation assay was done using the RT-
CESTM system (ACEA Biosciences, San Diego, CA).
Briefly, LM8G7 cells (5x104 cells) were added to ACEA
96X microtiter plates (e-plateTM) in 100 μl of medium
[30]. In an experiment, cell monolayer was made and
the various concentrations of compound 4g (2 to
75 μM), in 150 μL of DMEM were individually added.
The effect of the compounds on the proliferation of
LM8G7 or OVSAHO cells was continuously monitored
up to 48 hours for every 10 min. The proliferation was
monitored for a period of 70 h and expressed as a cell
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per the manufacturer’s instructions. A cell index was
plotted against time (for duplicate experiments). The
IC50 values were calculated from concentration-response
curves by a non-linear regression analysis using the
GraphPad Prism (GraphPad Prism Software Inc., San
Diego).
MTT assay
The anti-proliferative effect of the compound 4g on
MCF-7, melphalan-resistant multiple myeloma
(RPMI8226/LR5) MCF-10A or UV♀2 cells was deter-
mined by MTT dye uptake method as described previ-
ously [29]. Briefly, the cells were incubated in triplicate
in a 96-well plate in the presence or absence of indicated
concentration of compound 4g in a final volume of
0.2 ml for different time intervals at 37°C. Thereafter,
20 μL MTT solution (5 mg/ml in PBS) was added to
each well. After a 2 h incubation at 37°C, 0.1 ml lysis
buffer (20 % SDS, 50 % dimethylformamide) was added;
incubation was continued overnight at 37°C; and then
the optical density (OD) at 570 nm was measured by
Tecan plate reader.
Annexin V Assay
One of the early indicators of apoptosis is the rapid
translocation of the membrane phospholipid phosphati-
dylserine from the cell’s cytoplasmic interface to the
extracellular surface and its accumulation there, produ-
cing a loss of membrane symmetry that can be detected
using annexin V. Briefly, 1 x 106 MCF-7 cells were pre-
treated with compound 4g (30 μM) for various time
points and then subjected to annexin V staining. Cells
were washed, stained with FITC-conjugated anti-annexin
V antibody, and then analyzed with a flow cytometer
(BD FACS Calibur, BD Biosciences, US) [28].
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